Magnetic resonance imaging in clinical diagnosis of dementia;Die magnetresonanztomographie in der klinischen demenzdiagnostik

Radiologe

Volumn 43, Issue 7, 2003, Pages 513-520

  Schroder J ^a   Pantel, J ^b   Schonknecht P ^b   Essig, M ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b NONE

Author keywords

Alzheimer's disease; Diagnostic procedures; Early diagnosis; Magnetic resonance imaging

Indexed keywords

DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DEMENTIA; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; SOCIAL PSYCHOLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRIEF PSYCHIATRIC RATING SCALE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0042092060     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-003-0924-5     Document Type: Article

References (26)

1. Bickel H (2002) Epidemiologie der Demenz. In: Beyreuther K, Einhäupl KM, Förstl H, Kurz A (Hrsg) Demenzen. Grundlagen und Klinik. Thieme, Stuttgart New York
2. Folstein M, Folstein S, McHugh P (1975) "Mini-mental-state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 26:231-245
3. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A (1994) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 44:609-614
4. Shulman KI, Gold DP et al. (1993) Clock-drawing and dementia in the community: a longitudinal study. Int J Geriatr Psychiatr 8:487-496
5. Spreen O, Strauss E (1991). A compendium of neuropsychological tests. Oxford University Press, New York
6. Schröder J, Pantel J, Förstl H (2003) Gerontopsychiatrie. In: Kruse A, Martin M (Hrsg) Lehrbuch der Gerontologie: Alternsprozesse in multidisziplinärer Sicht. Huber, Bonn, im Druck
7. Schröder J, Kratz B, Pantel J, Minnemann E, Lehr U, Sauer H (1998) Prevalence of mild cognitive impairment in an elderly community sample. J Neural Transm 54:51-59
8. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurol 23:87-97
9. Jensen M, Schröder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 45(4):504-511
10. Schönknecht P, Pantel J, Hunt A, Volkmann M, Buerger K, Hartmann T, Hampel H, Schröder J (2003) Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett 339:172-174
11. Schönknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig M, Amann M, Zanabili N, Bardenheuer H, Hunt A, Schröder J (2003) Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared to vascular dementia but do not correlate with measures of cerebral atrophy. Psych Res, in press
12. Schröder J, Pantel J, Ida N, Essig M, Hartmann T, Knopp MV, Schad LR, Sandbrink R, Sauer H, Masters CL, Beyreuther K (1997) Cerebral changes and cerebrospinal fluid-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiat 2:505-507
13. Schröder J, Pantel J (1999) Morphologische und funktionelle Bildgebung. In: Förstl H (Hrsg) Alzheimer-Demenz. Springer, Berlin Heidelberg New York
14. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259
15. Pantel J, Schröder J, Schad LR, Friedlinger M, Knopp MV, Schmitt R, Geißler M, Blüml S, Essig M, Sauer H (1997) Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type. Psychol Med 27:221-229
16. Pantel J, Hüger DR, Kratz B, Essig M, Schröder J (2003) Parahippocampal volume reduction in aging-associated cognitive decline. Am J Psychiatry 160:379-382
17. Pantel J, Schönknecht P, Essig M, Schad LR, Amann M, Schröder J (2002) Follow-up of structural brain changes in Alzheimer's disease revealed by quantitative MRI-potential use for monitoring drug related changes. Drug Dev Res 56: S1-56
18. Pantel J, Schröder J, Essig M, Popp D, Dech H, Knopp MV, Schad LR, Eysenbach K, Friedlinger M (1997) Quantitative magnetic resonance imaging in late onset depression and primary degenerative dementia. J Affect Dis 42:69-83
19. Pantel J, Schröder J, Essig M, Schneider G, Eysenbach K, Jauss M, von Kummer R, Baudendistel K, Schad LR, Knopp MV (1998) In vivo quantification of brain volumes in vascular dementia and Alzheimer's disease - a MRI-based volumetric study. Dement Geriatr Cogn Dis 9:309-316
20. Herholz K, Salmon E, Perani D et al. (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 1:302-316
21. Cummings JD (2003) Use of cholinesterase inhibitors in clinical practice. Evidende-based recommendations. Am J Geriatr Psychiatry 11:2
22. Förstl H (2002) Symptomatische Therapie der Alzheimer-Demenz. Handbuch der Betreuung und Ptlege von Alzheimer-Patienten. Thieme, Stuttgart New York
23. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris ST, Möbius HJ (2003) Memantine in moderate-to-severe Alz-heimer's disease. N Engl J Med 348:14
24. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Somins K (1998) Cholesterol depletion inhibits the generation of b-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464
25. Sjögren M, Gustafsson K, Syversen ST, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K (2003) Treatment with simvastatin in patients with Alzheimer's disease lowers both a-and b-cleaved amyloid precursor protein. Dement Geriatr Cogn Dis 16:25-30
26. Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T,v. Bergmann K, Beyreuther K, Schröder J (2002) Cerebrospinal fluid 245-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett: 324:83-85